LISATA THERAP.INC.DL-001 Cash Flow-to-Debt Ratio
LISATA THERAP.INC.DL-001 cash flow-to-debt ratio. LISATA THERAP.INC.DL-001 (8NE) has a Cash Flow-to-Debt Ratio of -0.87x as of June 2026, meaning its operating cash flow of €-2.65 Million could theoretically repay -1% of its total liabilities (€3.04 Million) in one year. See LISATA THERAP.INC.DL-001 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LISATA THERAP.INC.DL-001 (2021–2025)
Cash flow-to-debt ratio of LISATA THERAP.INC.DL-001 from 2021 to 2025. Historical debt coverage capacity for LISATA THERAP.INC.DL-001 across 5 annual periods. Also explore 8NE net asset momentum to track the company's year-over-year net asset growth rate.
LISATA THERAP.INC.DL-001 Cash Flow-to-Debt Ratio by Year (2021–2025)
LISATA THERAP.INC.DL-001 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for LISATA THERAP.INC.DL-001. For the full cash flow conversion analysis, see 8NE cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.07x | €-15.95 Million | €3.14 Million | ▼ -49.0% |
| 2024 | -3.40x | €-19.36 Million | €5.68 Million | ▼ -15.6% |
| 2023 | -2.95x | €-20.03 Million | €6.80 Million | ▲ +6.6% |
| 2022 | -3.15x | €-21.17 Million | €6.71 Million | ▲ +29.0% |
| 2021 | -4.44x | €-22.25 Million | €5.01 Million | — |